Eli Lilly Vs. Hims & Hers In DTC Weight Loss Market? - There Is Only One Winner
Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.
Fierce Healthcare20h
DTC obesity med market heats up: Eli Lilly taps knownwell, Hims & Hers adds new weight loss meds to platform
Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...
‘Hold the Phone,’ Says Morgan Stanley on Hims & Hers Health Stock (HIMS)
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Zacks.com on MSN14h
Novo Nordisk (NVO) Stock Moves -1.67%: What You Should Know
Novo Nordisk (NVO) ended the recent trading session at $67.10, demonstrating a -1.67% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss of ...